Ergoteles’s Arcadia Biosciences RKDA Stock Holding History

Ergoteles’s Portfolio RKDA Stock Details RKDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,163	Closed	-$12.6K	–	1687
2022 Q4	$12.6K	Buy	+1,163	New	+$16.6K	﹤0.01%	1364

Other funds holding RKDA

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ergoteles's RKDA Position: Q1 2023 in Review

Ergoteles sold out of Arcadia Biosciences (RKDA) in Q1 2023, closing a stake of 1,163 shares — an estimated $12.6K sold.

Ergoteles first reported a position in RKDA in Q4 2022 and held it in 1 quarter. The position peaked at $12.6K in Q4 2022. 15 funds tracked by Wall St. Rank hold RKDA as of Q1 2023.

Ergoteles reported no remaining Arcadia Biosciences position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 1,163 Arcadia Biosciences shares in Q1 2023, an estimated $12.6K.
Ergoteles first reported a position in Arcadia Biosciences in Q4 2022 and held it in 1 quarter.
Ergoteles's Arcadia Biosciences position peaked at $12.6K in Q4 2022.
15 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.